Psychological Symptoms and Stress Are Associated With Decrements in Attentional Function in Cancer Patients Undergoing Chemotherapy
- PMID: 30998605
- DOI: 10.1097/NCC.0000000000000713
Psychological Symptoms and Stress Are Associated With Decrements in Attentional Function in Cancer Patients Undergoing Chemotherapy
Abstract
Background: Decrements in attentional function-perceived effectiveness in everyday functioning related to cognitive dysfunction-are frequently reported by cancer patients during treatment. However, patients vary widely in their experiences of changes in attentional function.
Objective: The aim of this study was to understand differences in attentional function among cancer patients during chemotherapy.
Methods: Patients (n = 1329) undergoing chemotherapy were assessed at 6 time points during 2 rounds of chemotherapy. Latent profile analysis was used to identify subgroups of patients based on patterns in changes on the Attentional Function Index. Differences among the subgroups in demographic and clinical characteristics, psychological symptoms, and stress were evaluated.
Results: Three latent classes (ie, high, moderate, and low attentional function) were identified. Patients in the low and moderate classes were younger, more likely to be female, and less likely to be employed compared with those in the high class. Patients in the low class had higher levels of depressive and anxiety symptoms, cancer-related distress, and perceived stress compared with those in the moderate class, who, in turn, reported higher levels of these symptoms compared with those in the high class.
Conclusions: Different experiences of changes in self-perceived attentional function are associated with psychological symptoms in cancer patients.
Implications for practice: Relationships between changes in attentional function and psychological symptoms and stress suggest that clinicians should attend to the potential that patients' cognitive and psychological experiences may be closely linked and may need to be addressed as related phenomena. Clinical trials are needed that evaluate treatments for both attentional and psychological symptoms.
Similar articles
-
Worse Morning Energy Profiles Are Associated with Significant Levels of Stress and Decrements in Resilience in Patients Receiving Chemotherapy.Semin Oncol Nurs. 2024 Oct;40(5):151718. doi: 10.1016/j.soncn.2024.151718. Epub 2024 Aug 20. Semin Oncol Nurs. 2024. PMID: 39164158
-
Co-occuring symptoms in older oncology patients with distinct attentional function profiles.Eur J Oncol Nurs. 2019 Aug;41:196-203. doi: 10.1016/j.ejon.2019.07.001. Epub 2019 Jul 2. Eur J Oncol Nurs. 2019. PMID: 31358253 Free PMC article.
-
Distinct attentional function profiles in older adults receiving cancer chemotherapy.Eur J Oncol Nurs. 2018 Oct;36:32-39. doi: 10.1016/j.ejon.2018.08.006. Epub 2018 Aug 22. Eur J Oncol Nurs. 2018. PMID: 30322507 Free PMC article.
-
The physical, psychological and social experiences of alopecia among women receiving chemotherapy: An integrative literature review.Eur J Oncol Nurs. 2020 Dec;49:101840. doi: 10.1016/j.ejon.2020.101840. Epub 2020 Sep 28. Eur J Oncol Nurs. 2020. PMID: 33120213
-
Chemotherapy-related change in cognitive function: a conceptual model.Oncol Nurs Forum. 2007 Sep;34(5):981-94. doi: 10.1188/07.ONF.981-994. Oncol Nurs Forum. 2007. PMID: 17878127 Review.
Cited by
-
A scoping review of cognitive assessment tools and domains for chemotherapy-induced cognitive impairments in cancer survivors.Front Hum Neurosci. 2023 Feb 20;17:1063674. doi: 10.3389/fnhum.2023.1063674. eCollection 2023. Front Hum Neurosci. 2023. PMID: 36891148 Free PMC article.
-
Self-reported cancer-related cognitive impairment is associated with perturbed neurotransmission pathways.J Neural Transm (Vienna). 2025 Feb;132(2):275-286. doi: 10.1007/s00702-024-02824-9. Epub 2024 Sep 26. J Neural Transm (Vienna). 2025. PMID: 39325169 Free PMC article.
-
Effectiveness of the Unified Barlow Protocol (UP) and neuropsychological treatment in cancer survivors for cognitive impairments: study protocol for a randomized controlled trial.Trials. 2022 Sep 30;23(1):819. doi: 10.1186/s13063-022-06731-w. Trials. 2022. PMID: 36175973 Free PMC article.
-
Natural trajectory subclasses of cognitive impairment in breast cancer patients experiencing insomnia.Cancer. 2025 Apr 15;131(8):e35816. doi: 10.1002/cncr.35816. Cancer. 2025. PMID: 40219873 Free PMC article.
-
Distinct sleep disturbance and cognitive dysfunction profiles in oncology outpatients receiving chemotherapy.Support Care Cancer. 2022 Nov;30(11):9243-9254. doi: 10.1007/s00520-022-07350-6. Epub 2022 Sep 6. Support Care Cancer. 2022. PMID: 36066629
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical